Recent product introductions, including MOSAIQ® Plaza and Elekta Unity MR-Linac, as well as continued advances to the family of HD linear accelerators and MR-guided brachytherapy, demonstrate Elekta's continued commitment to advancing oncology care. Features in the new solutions include higher personalization, improved workflows, better precision and more intelligence through automation as well as through analytics and supporting through evidence-driven decision support.

"Transforming cancer care is more than just technology innovation - it must address treatment gaps and process inefficiencies that drive up healthcare costs and produce suboptimal patient outcomes," said Richard Hausmann, President and CEO, Elekta. "Healthcare reforms in the USA and elsewhere greatly benefit from Elekta's Precision Radiation Medicine strategy. Our several unique technologies, from Elekta Unity to brachytherapy and Leksell Gamma Knife, enable more hypofractionation possibilities and expand the range of indications."

ASTRO attendees are invited to visit Elekta booth 3431 to learn more about how the company is making Precision Radiation Medicine the standard of value-based healthcare with innovative radiation delivery systems and software solutions.

For real-time updates from our educational events and the ASTRO show floor, follow @Elekta (https://twitter.com/Elekta)on Twitter. To learn more about Elekta at ASTRO, visit elekta.com/ASTRO (http://www.elekta.com/ASTRO).

Elekta Unity has CE mark and 510(k) clearance but is not available in all markets. MOSAIQ Plaza is not available in all markets.

# # #

For further information, please contact:
Oskar Bosson, Global EVP Corporate Communications and Investor Relations
Tel: +46 70 410 7180, e-mail: Oskar.Bosson@elekta.com
Time zone: CET: Central European Time 

Raven Canzeri, Global Public Relations Manager
Tel: +1 770 670 2524, e-mail: raven.canzeri@elekta.com
Time zone: ET: Eastern Time 

About Elekta
For almost five decades, Elekta has been a leader in precision radiation medicine. Our nearly 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to - and benefits from - more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit elekta.com (http://www.elekta.com/) or follow @Elekta (https://twitter.com/Elekta)on Twitter.